[Seite 47↓]

LITERATURVERZEICHNIS

1 .Acheampong, A.., Shackleton, M., Tang-Liu, D., et al., Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr. Eye Res. 18 (2): 91-103 (1999)

2. Ahmed, I., Patton, T. F., Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthal. Vis. Sci. 26: 584-587 (1985).

3 .Alexander, L. N. and Wilcox, C. M., A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. Aids Res. Hum. Retroviruses 13 :301-304 (1997).

4 .American Academy of Ophthalmology – Basic and Clinical Science Course Section 2: Fundamentals and Principles of Ophthalmology. 1994-1995 :252.

5 .Attal, M., Harousseau, J-L., Stoppa A-M., et al., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 335: 91-7 (1996).

6 .Aumatell, A., Enantiomeric differentiation of a wide range of pharmacologically active substances by capillary electrophoresis using modified ß-cyclodextrins. J. Chromatogr. A. 686: 293-307 (1994).

7 .Baatz, H., Tönessen, B., Prada, J., Pleyer, U., Thalidomide Inhibits Leukocyte-Endothelium Interaction in Endotoxin-Induced Uveitis. Ophthalmic Res. 33: 256-263 (2001).

8 .Bartlett, J. D., Jaanus, S. D., Clinical Ocular Pharmacology. Butterworth Pub. Seite 7 (1989).

9. Battegay, E. J., Angiogenesis: mechanistic insights, neovascular diseases and therapeutic prospects. J. Mol. Med. 73 :333-346 (1995).

10. Baumann, M., Über das Ziliarfortsatzgefäßsystem. Ber. Dtsch. Ophthal. Ges. 48: 364 (1930).

11 .Bellamy, W. T., Richter, L., Frutiger, Y., Grogan, T. M., Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59: 728-33 (1999).

12 .Bertelmann, E., Knapp, S., Rieck, P., et al., Transkornealer-parakornealer Penetrationsweg für lokal applizierte Pharmaka am Auge. Mycophenolat Mofetil als Modellstubstanz. Ophthalmologe 9: 696-701 (2003).

13. Bloomfield, S. E., Miyata, T., Dunn, M. W., et al., Soluble gentamicin ophthalmic inserts as a drug delivery system. Arch. Ophthal. 96: 885-887 (1978).

14 .Choa, N., Nadermanee, A., O’Donnell, M. R., et al., Thalidomide for salvage therapy in chronic graft vs host disease. Blood 86 (6): 3604-3609 (1995).

15 .Cogan, D., and Hirsch, E., The Cornea: VII. Permeability to weak electrolytes. Arch. Ophthal. 32: 276 (1944).

16 .Corral L. G., Haslett, P. A. J., Muller, G. W., et al., Differential cytokine modulation and T cell activation by two distict classes of thalidomide analogs which are potent inhibitors of TNF- α . J Immunol. 163 :380-6 (1999).

17 .Corral, G. C., Kaplan, G., Immunomodulation by thalidomide and thalidomide analogues. Annals of the rheumatic diseases 88(suppl 1): 107-13 (1999).

18 .Corral, L. G:, Muller, G. W., Moreira, A. L., et al., Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor- α Inhibitory Activity. Mol. Med. 2 (4): 506-515 (1996).

19 .D’Amato, R. J., Lougham, M. S., Flynn, E., Folkman, J., Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91: 4082-5 (1994).

20.Damiano, J. S., Cress, A. E., Hazelhurst L. A., Shtil, A. A., Dalton, W. S., Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658-67 (1999).

21 .Dárcy, P. F., Griffin, J. P., Thalidomide revisited. Adverse Drug React. Toxicol. Rev. 13 (2): 65-77 (1994).


[Seite innerhalb Literaturhinweis 48↓]

22 .Davidson, S. K., Summers, J. B., Inhibitors of TNF- α synthesis . Exp. Opin. Ther. Pats . 5: 1087-1100 (1995).

23 .Denman, A. M., Graham, E. Howe, L., et al., Low dose thalidomide treatment of Behcet´s syndrome. In: Wechsler B, Codeau P, eds. Behcet´s Disease. Proceedings of the 6th international Conference on Behcet´s disease, 30 June-1 July 1993; Paris, France, Amsterdam. Excerpta Medica 649-53 (1993).

24 .Doane, M. G., Jensen, A. D., Dohlman, C. H., Penetration Routes of Topically Applied Eye Medications. Am. J. of Ophthal. 85: 383-386 (1978).

25. Edelhauser, H. F., Maren, T. H., Permeability of human cornea and sclera to sulfonamide cabonic anhydrase inhibitors. Arch. Ophthal. 106: 1110-1115 (1988).

26 .Ehlers, N., The precorneal film, biomicroscopical, histological and chemical investigations . Acta Ophthal. (Suppl.)(Copenh.) 81 (1965).

27 .Ehrlich, G. E., Vasculitis in Behcet’s disease. Int. Rev. Immunol. 14 :81-8 (1997).

26 .Eriksson, T., Björkman, S., Höglund, P., Clinical pharmacology of thalidomide . Eur. J. Clin. Pharmacol. 57: 365-376 (2001).

29 .Eriksson, T., Björkman, S., Roth, B., et. al., Stereospecific Determination, Chiral Inversion in Vitro and Pharmacokinetics in Humans of the Enantiomers of Thalidomide: Kinetics of the Enantiomers of Thalidomide. Chirality 7:44-52 (1995).

30 .Eriksson, T., Björkman, S., Fyge, A., Ekberg, H., Determination of thalidomide in plasma and blood by high-performace liquid chromatography: avoiding hydrolytic degradation, J. chromatography, J. Chromatogr. 172: 490-492 (1979)

31 .Florence, A. L., Is Thalidomide to Blame? Brit. Med. J. Dec. 31, 1960:1954.

32 .Freedmann, K. A., Klein, J. W., Crosson, C. E., Beta-Cyclodextrins enhance Bioavailability of Pilocarpine. Curr. Eye Res. 12: 641-647 (1993).

33 .Freeman, W. R., Blumenkranz, M. S., Age-related Macular Degeneration: Is Help on the Way?. Ophthal. 105 (9): 1585-1586 (1998).

34 .Friedberg, M., Pleyer, U., Mondino, B. J., Device Drug Delivery: Collagen Shields, Ionophoresis, Pumps. Ophthalmology 98: 725-732 (1991).

35. Friedlander, M., Brooks, P. C., Shaffer, R. W., et al., Definition of two angiogenic pathways by distinct alpha integrins. Science 270: 1500-1502 (1995).

36 .Fullerton, P. M., O’Sullivan, D. J., Thalidomide neurophathy: a clinical, electrophysiological and histological follow-up study. J. Neurol. Neurosurg. Psychiatry 31: 543-551 (1968).

37 .Gad, S. M., Shannon, E. J., Krotoski, W. A., et al., Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males . Lepr Rev. 56: 35-39 (1985).

38. Gardner-Medwin, J. M. M., Smith, N. J., Powell, R. J., Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet´s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis . 53: 828-832 (1994).

39 .Gori, A., Rossi, M. C., Marchetti, G., et al., Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. AIDS 14 (12 ): 1859-1861 (2000).

40 .Green, K., Kearse, C., Ocular penetration of topical Δ 9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Cur. Eye Res. 21(1): 566-570 (2000)

41 .Grosshans, E., Illy, G., Thalidomide therapy for inflammatory dermatoses. Int. J. Dermatol. 23: 598-602 (1984).

42 .Grunfeld, C., Feingold, K. R., Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N. Engl. J. Med. 327: 329-337 (1992).


[Seite innerhalb Literaturhinweis 49↓]

43 .Guenter, P., Murahainen, N., Simons, G., et al., Relationship among nutritional status, disease progression and survival in HIV infection. J. Acquir. Immune. Defic. Syndr . 6: 1130-1138 (1993).

44 .Guex-Crosier, Y., Pittet, N., Herbort, C. P., The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats. Graefe’s Arch. Clin. Exp. Ophthal. 233: 90-93 (1995).

45.Günzler, V., Thalidomid – A Therapy for the Immunological Consequences of HIV Infection. Med. Hypotheses 30: 105-109 (1989).

46 .Gutierrez-Rodriguez, O., Starusta-Bacal, P., Gutierrez-Montes, O., Thalidomide-induced neuropathy in rheumatoid arthritis. Arthritis Rheum. 31: 145-146 (1988).

47.Hallek, M., Leif Bergsagel, P., Anderson, K. C., Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91 : 3-21 (1998).

48 .Hamuryudan, V., Mat, C., Saip, S., et al., Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome. Ann. Int. Med. 128 (6): 443-450 (1998).

49 .Hamuryudan, V., Özdogan, H., Yazici, H., Other forms of vasculitis and pseudovasculitis. Ballières Clin Rheumatol. 11:335-55 (1997).

50 .Haslett, P. A., Corral, L. G., Albert, M., et al., Thalidomide costimulates primary human T-lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187: 1885-1892 (1998).

51 .Haslett, P., Tramontana, J., Burroughs, M., et al., Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 24: 1223-1227 (1997).

52 .Heney, D., Norfolk, D. R., Wheeldon, J., et al., Thalidomide treatment for chronic graft versus host disease. Br. J. Haematol. 78: 23-27 (1991).

5 3.Hess, C. W., Hunziker, T., Kupfer, A. Ludin, H. P., Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J. Neurol. 223: 83-9 (1986).

54. Hollwich, F., Einführung in die Augenheilkunde. 6. überarbeitete Aufl. G. Thieme Verlag Stuttgart, Seite 9 (1968).

55 .Hollwich, F., Einführung in die Augenheilkunde. 6. überarbeitete Aufl. G. Thieme Verlag Stuttgart, Seite 3 (1968).

56 .Holm, O., and Krakau, C., Measurement of the flow of aqueous humor according to a new principle. Experientia 22: 773 (1966).

57 .Hussein, M. A., Research on Thalidomide in Solid Tumors, Hematologic Malignancies, and Supportive Care. Oncology. 14(Suppl 12): 9-15 (2000).

58 .Jacobson, J. M., Greenspan, J. S., Spritzler, J., et al, Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Eng. J. Med . 336 (21): 1487-1493 (1997).

59 .Jacobson, J. M., Spritzler, J., Fox, L., et al., and the National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group, Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J. Infect. Dis . 180 :61-67 (1999).

60 .Jansen, T., Beta-Cyclodextrins as vehicles in eye-drop formulations: An evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxicity Res . 7: 459-468 (1990).

61.Järvinen, K., The effect of a modified ß-cyclodextrin, SBE4-ß-CD, on the aqueous stability and ocular absorption of pilocarpine. Curr. Eye Res. 13: 897-905 (1994).

62 .Jorizzo, J. L., Schmalstieg, F. C., Solomon, A. R. Jr, et al., Thalidomide effects in Behcet´s syndrome and pustular vasculitis. Arch. Intern. Med. 146: 878-81 (1986).


[Seite innerhalb Literaturhinweis 50↓]

63 .Joussen, A. M., Germann, T., Kirchhof, B. Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. Graefe´s Arch Clin Exp Ophthal. 237 :952-961 (1999).

64.Kaiser, R. J., and Maurice, D. M., The diffusion of fluorescein in the lens. Exp. Eye Res. 3: 156 (1964).

65 .Kanai, A., The Effect on the Cornea of Alpha Cyclodextrin Vehicle for Cyclosproin Eye Drops. Transplan. Proc. 21 (1): 3150-3152 (1989).

66 .Kaplan, G., Cytokine Regulation of Disease Progression in Leprosy and Tuberculosis. Immunobiol. 191:564-568 (1994).

67 .Keipert, S., Interactions between cyclodextrins and pilocarpine – as an example of hydrophilic drug. Int. J. Pharm. 142: 153-162 (1996).

68 .Klausner, J. D., Freedman, V. H., Kaplan, G., Thalidomide as an anti-TNF- α inhibitor: Implications for clinical use. Clin Exp Immunol. 81: 219-223 (1996).

69 .Klausner, J., Freedman, V. H., and Kaplan, G., A short Analytical Review Thalidomid as an Anti-TNF- α Inhibitor: Implications for Clinical Use. Clin. Immunol. &. Immunpatholo. 81 (3): 219-223 (1996).

70 .Klein, M., Beitrag zur Resorption aus Augensalbe: II. Die Resorption des Atropins. Albrecht Von Graefes Arch. Ophthal. 129: 413 (1933).

71 .Klyce, S. D., Transport of Na, Cl, and water by the rabbit corneal epithelium at resting potential. Am. J. Physiol. 228: 1446 (1975).

72 .Knop, J., Bonsmann, G., Happle, R., Ludolph, A., et al., Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br. J. Dermatol. 108: 461-466 (1983).

73 .Koch, Heinrich P., Löslichkeits- und Stabilitätsverbesserung von Thalidomid durch Bildung von Einschlußkomplexen mit Cyclodextrinen. Arch. Pharm. (Weinheim) 321: 371-373 (1988).

74 .Koevary, S.B., Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond. Curr. Drug Met. 4: 213-222 (2003)

75 .Kogiso, M., Tanouchi, Y., Mimura, Y., Nagasawa, H., Himeno, K., Endotoxin-induced uveitis in mice I. Induction of uveitis and role of T-lymphocytes. Jpn. J. Ophthalmol. 36: 281-290 (1992).

76 .Kotler, D. P., Tierney, A. R., Wang, J., Pierson, R. N., Magnitude of body cell-mass depletion and the timing of death from wasting in AIDS. Am. J. Clin. Nutr. MWR . 50: 444-447 (1989).

77 .Kotler, D. P., Wang, J., Pierson, R. N., Body composition studies in patients with the acquired immunodeficiency syndrome. Am. J. Clin. Nutr. 42: 1255-1265 (1985).

78 .Krenn, M., Gamcsik, M. P., Vogelsang, G. B., et. al., Improvements in Solubility and Stability of Thalidomide upon Complexation with Hydroxypropyl-ß-Cyclodextrin. J. of Pharm. Sciences 81 (7): 685-689 (1992).

7 9.Kruse, F. E., Joussen, A. M., Rohrschneider, K., et. al., Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe´s Arch. Clin. Exp. Ophthalmol. 236: 461-466 (1998).

80 .Lagueny, A., Rommel, A., Vignolly, B., et al., Thalidomide Neuropathy: An Electrophysiologic Study. Muscle & Nerve 9: 837-844 (1986).

81 .Landis, S. H., Murray, T, Bolden, S., Wingo, P. A., Cancer statistics. CA Cancer J. Clin. 49: 12 (1999).

82 .Lee, V. H., Robinson, J. R., Review: topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 2: 67-108 (1986).

83 .Loftsson, T., 2-Hydroxypropyl-ß-cyclodextrin in topical carbonic anhydrase inhibitor formulations. Eur. J. Pharm. Sci . 1: 175-180 (1994).

84.Loftsson, T., Stefánsson, E., Cyclodestrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. ACTA Ophthalm. Scandin. 80: 144-150 (2002)


[Seite innerhalb Literaturhinweis 51↓]

85 .Marriott, J. B., Muller, G., Dalgleish, G., Thalidomide as an emerging immunotherapeutic agent. Immun. Today 20: 538-40 (1999).

86 .Maurice, D. M., Ocular pharmacokinetics . In: Sears ML, ed Pharmacology of the Eye. New York: Springer-Verlag 19-116 (1984).

87 .Maurice, D. M., The dynamics and drainage of tears. Int. Ophthalmol. Clin. 13 (1): 103 (1973).

88 .Maurice, D., Structures and fluids involved in the penetration of topically applied drugs . Inter. Ophthal. Clinics 20 (3): 7-20 (1980).

89 .McCarty, M. F., Thalidomide may impede cell migration in primates by down-regulating integrin ß-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Medical Hypotheses 49: 123-131 (1997).

90 .McHugh, S. M., Rifkin, I. R., Deighton, J., et al., The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. 99: 160-167 (1995).

91.Mishima, S., Some physiological aspects of the precorneal tear film. Arch. Ophthal . 73:233 (1965).

92 .Moriera, A. L., Sampaio, E. P., Zmuidzinas, A., et al., Thalidomide exerts its inhibitory action on tumor necrosis factor- α by enhancing mRNA degradation. J. Exp. Med. 177: 1675-1680 (1993).

93 .Muller, G. C., Chen, R., Huang, S-Y, et al., Amino-substituted thalidomide analogs: potent inhibitors of TNF- α production. Bioorg. Med. chem. Lett. 9: 1625-30 (1999).

94 .Ochonisky, S., Verroust, J., Bastiju-Garin, S., et al., Thalidomide neuropathy: incidence and electrophysiologic findings in 42 patients . Arch. Dermatol. 130: 66-69 (1994).

95 .Olsen, T. W., Edelhauser, H. F., Lim, J. I., et al., Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthal. Vis. Sci. 36: 1895-1903 (1995).

9 6.Ota, Y., Mishima, S., and Maurice, D., Endothelial permeability of the living cornea to fluorescein. Invest. Ophthal. 13: 945 (1974).

97 .Parman, T. Wiley, M. J., Wells, P. G., Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. med. 5: 582-5 (1999).

98 .Pleyer, U., Grammer, J., Bachmann, W., Thiel, H.-J., Kollagenlinsen: Anwendungen und therapeutische Möglichkeiten. Akt. Augenheilk. 20: 173-183 (1995).

99 .Pleyer, U., Liekfeld, A., Baatz, H., Hartmann C., Pharmakologische Modulation immunmediierter Erkrankungen des Auges, Klin. Monatsbl. Augenheilkd. 214: 160-170 (1999).

100 .Raje, N., Anderson, K., Thalidomide – A Revival Story. N. Engl. J. Med. 341: 1606-1609 (1999).

101 .Rajewski, R. A., Valentino, S. J., Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery . J. Pharm. Sci. 85.11: 1142-1169 (1996).

102 .Rajkumar, S. V., Thalidomide in Hematologic and Oncologic Disease . Oncology 14 (Suppl.13): 9-10 (2000).

103 .Reyes-Teràn, G., Sierra-Madero, J. G., Martìnez del Cerro, V., et. al., Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10: 1501-1507 (1996).

104 .Ribatti, D., Vacca, A., Nico, B., et al., Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br. J. Cancer 79: 451-5 (1999).

105 .Ryan, J., Coleman, J., Pedersen, J., Benson, E., Thalidomide to treat oesophageal ulcers in AIDS. N. Engl. J. Med. 327: 208-209 (1992).


[Seite innerhalb Literaturhinweis 52↓]

106 .Sampaio, E. P., Sarno, E. N., Galilly, R., et al., Thalidomide selectively inhibits tumor necrosis factor- α production by stimulated human monocytes. J. Exp. Med. 173 :699-703 (1991).

107 .Saari, M. K., Ali-Meikkiliä, T., Vuori, M.L., et al., Absorption of ocular timolol: drug concentrations and ß-receptor binding activity in the aqueous humour of the treated and contralateral eye. ACTA Ophthal . 71: 671-676 (1993)

108 .Sylan, T. Saltik, I., Thalidomide in the treatment of Behcet´s syndrome. Arch.Dermatol. 118: 536 (1982).

109 .Schlossberg, H., Klumpp, T., Sabol, P., et al., Severe cutaneous ulceration following treatment with thalidomide for GVHD. Bone Marrow Transplant. 27 (2): 229-30 (Jan. 2001).

110 .Schoenwald, R. D., Desphpande, G. S., Rethwisch, D. G., et al., Penetration into the anterior chamber via the conjunctival/scleral pathway. J. Ocular Pharm. Therap. 13: 41-59 (1997).

111 .Schoenwlad, R. D., Pharmacokinetics in Ocular Drug Delivery. In: Edman P. Biopharmaceutics of Ocular Drug Delivery . Ann Arbor MI: CRC Press; Chap 10 (1992).

112 .Schoenwald, R. D., Ocular drug delivery pharmacokinetic considerations. Clin. Pharmacokinet. 19: 225-269 (1994).

113 .Schoenwald, R. D., Oculare Pharmacokinetics. Textbook of Ocular Pharmacology , ed. Zimmerman, et al. Lippencott-Raven Publishers, Philadelphia 119-150 (1997).

114 .Schumacher, H., Smith, R. L., Williams, R. T., The Metabolism of Thalidomide: The Spontaneous Hydrolysis of Thalidomide in Solution. Brit. J. Pharmacol. 25: 324-337 (1994).

115 .Sharpstone, D., Rowbottom, A., Nelson, M., et al., Faecal tumour necrosis factor-alpha in individuals with HIV-related diarrhoea. AIDS (United States) 10 (9): 989-94 (1996).

116 .Shek, L. P., Lee, Y. S., Lee, B. W., Thalidomide Responsiveness in an Infant with Behcet´s Syndrome. Pediatrics 103 :1295-1297 (1999).

117 .Sherskin, J., Study with nine thalidomide derivatives in the lepra reaction. Dermatol. 17:82 (1978).

118 .Sheskin, J., The Treatment of Lepra Reaction in Lepromatous Leprosy: Fifteen Years‘ Experience with Thalidomide. Int. J. Dermatol. 19: 318-22 (1980).

119 .Shigetoshi, N., Saiichi, M., Pharmacokinetics of Instilled Drugs in the Human Eye. Intern. Ophthal. Clin. 20 (3): 33-49 (1980).

120 .Siefert, B., Keipert, S., Influence of alpha-cyclodextrin and hydroxyalkylated beta-cyclodextrin derivatives on the in vitro corneal uptake and permeation of aqueous pilocarpine-HCL solutions, J. Pharm. Sci. 86 (6): 716-720 (1997)

121 .Siefert, B., Siefert, B., Pleyer, U., Müller, M., Hartmann, C., Keipert, S ., Influence of cyclodextrins on the in vitro corneal permeability and in vivo distribution of thalidomide. J. Ocul. Pharmacol. Ther. (USA). 15 (5): 429-438 (Oct 1999)

122 .Sieg, J., and Robinson, J., Mechanistic studies on transcorneal permeation of pilocarpine. J. Pharm. Sci. 65: 1816 (1976).

123 .Silva, A. T., Bayston, K. F., Cohen, J., Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor- α in experimental gram-negative shock. J. Infect. Dis. 162: 421-427 (1990).

124 .Simpson, J. A., Thalidomide Neuropathy. Brit. Med. J. Dec. 14, 1963:1527.

125 .Singhal, S, Mehta, J., Desikan, R, et al., Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341: 1565-71 (1999).

126 .Soylan, T. Saltik, I., Thalidomide in the treatment of Behcet´s syndrom. Arch. Dermatol. 118:536 (1982).


[Seite innerhalb Literaturhinweis 53↓]

127 .Stella, V. J., Rajewski, R. A., Cyclodextrins: Their Future in Drug Formulation and Delivery. Pharm. Res. 14 (5): 556-567 (1997).

128 .Stephens, T. D., Bunde, C. J. W., Fillmore, B. J., Mechanism of Action in Thalidomide Teratogenesis . Biochem. Pharmacol. 59: 1489-1499 (2000).

129 .Stieter, R. M., Kunkel, S. J., Bone, R. C., Role of tumor necrosis factor- α in disease states and inflammation. Crit. Care Med. 21:447-463 (1993).

130 .Szejtli, J., Medicinal applications of cyclodextrins. Med. Res.Rev. 14: 353-386 (1994).

131 .Tabin, C. J., A developmental model for thalidomide defects . Nature 396:322-323 (1998).

132 .Tan, A. Y., LeVatte, T.L., Archibald, M.L., et al. Timolol Concentrations in Rat Ocular Tissues and Plasma After Topical and Intraperitoneal Dosing. J. Glaucoma. 11: 134-142 (2002).

133 .Tetsumi, I., Kaneto, U., Pharmaceutical applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation. J. Pharm. Sci. 86 2: 147-162 (1997).

134 .Thalidomid capsules (thalidomide) prescription product insert. Celgene, Warren, NJ, revised August 1998.

135 .Thiel, R. , Atlas der Augenheilkunde. 6. Aufl. G. Thieme Verlag, Stuttgart, Seite 64 (1963).

136 .Tracey, K. J., Fong, Y, Hesse, D. G., et al., Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia . Nature 330: 662-664 (1987).

137 .Trolle-Lassen, C., Investigations into the sensitivity of the human eye to hypo- and hypertonic solutions as well as solutions with unphysiological hydrogen ion concentrations. Pharm. Weekbl. 93: 148-155 (1958).

138 .Tseng, S., Pak, G., Washenik, K., et al. Rediscovering thalidomide: A review of ist mechanisms of action, side effects, and potential uses. J. Am. Acad. Dermatol. 35: 969-979 (1996).

139 .Usayapant, A., Karara, A. H., Narurkar, M. M., Effect of 2-hydroxypropyl-ß-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharm. Res . 8 (12):1495-1499 (1991).

140 .Vacca, A., Ribatti, D., Presta, M., et al., Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 :3064-73 (1999).

141 .Valentino, S. J., Rajewski, R. A., Cyclodextrins: Their Future in Drug Formulation and Delivery. Pharm. Res. 145: 556-567 (1997).

142 .Van Doorne, H., Interactions between Cyclodextrins and Opthalmic Drugs. Eur. J. Pharm. Biopharm. 39 (4): 133-139 (1993).

143 .Vedat, H., Cem, M., Sebahattin, S., et al., Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrom: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann. Internal Med. 128 (6): 443-450 (March 1998).

144 .Viraben, R., Dupre, A., Erythema nodosum following thalidomide therapy for Behcet´s disease. Dermatologica. 176 :107 (1988)

145 .Voigt, M., Kralinger, M., Kieselbach, G., Ocular Asprin Distribution: A comparison of Intravenous, Topical and Coulomb-Controlled Iontophoresis Administration. Invest. Ophthalmol. Vis. Sci. 43 :3299-3306 (2002).

146 .Walchner, M., Meurer, M., Plewig, G., et al., Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int. J. Derm. 29:383-388 (2000).

147 .Weng, W., Sasaki, H., Chien, D. S., et al., Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr. Eye Res. 10:571-579 (1991).


[Seite innerhalb Literaturhinweis 54↓]

148 .Whitcup, S., Pleyer, U., Lai, J., Lutz, S., Mochizuki, M., Chan, C., Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul. Immunol. & Inflammat. 6 (1): 51-56 (1998).

149 .Wolkenstein, P., Latarjet, J., Roujeau J. C., et al., Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:156-1589 (1998).

150 .Yazici, H., Chamberlain, M. A., Türün, Y, et al., A comparative study of the pathergy reaction among turkish and British patients with Behcet´s disease. Ann. Rheum. Dis. 43: 74-5 (1984).

151 .Yazici, H., Pazarli, H., Barnes, C. G., et al ., A controlled trial of azathioprine in Behcet´s syndrome. N. Engl. J. Med. 322:281-5 (1990).

152 .Yazici, H., Yurdakul, S. Hamuryudan, V., Behcet´s syndrome. How should we treat it?. Clin. Immunother. 3:102-7 (1995).

153 .Youle, M., Clabour, J., Farthing, C., et al., Treatment of resistant apthous ulceration with thalidomide in patients positive for HIV antibody. BMJ. 298:432 (1989).

154 .Youle, M., Clarbour, J. Furthing, C., Connolly, M., et al., Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ. 298 : 432 (1989).

155 .Yurdakul, S., Tüzüner, N., Yurdakul, I., et al., Gastrointestinal involvement in Behcet´s syndrome: a controlled study. Ann. Rheum. Dis. 55:208-10 (1996).

156 .Zwingenberger, K., Wendt, S., Immunomodulation by thalidomide: systemic reveiw of the literature and of unpublished observations. J. Inflamm . 46:177-211 (1996).


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
XDiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
16.06.2005